Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trialRobin Kate Kelley, Ming‐Huang Chen, Thomas Yau et al.|The Lancet|2023Cited by 1k
Regorafenib plus nivolumab in unresectable hepatocellular carcinoma: the phase 2 RENOBATE trialHyung‐Don Kim, Changhoon Yoo|Nature Medicine|2024Cited by 65
Integrative analysis of risk factors for immune-related adverse events of checkpoint blockade therapy in cancerChanghwan Sung, Sook Ryun Park, Jinhyeon An et al.|Nature Cancer|2023Cited by 46